Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

534
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
534
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

672
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
672
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

176
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
176
Cardiovascular Drugs: Classification based on Therapeutic Indications01:18

Cardiovascular Drugs: Classification based on Therapeutic Indications

2.9K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.9K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

188
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
188
Hypertension and Regulation of Blood Pressure01:18

Hypertension and Regulation of Blood Pressure

2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changes in Upper Airway Anatomy and Apnea-Hypopnea Index in Patients with Obstructive Sleep Apnea Undergoing Bariatric Surgery: A Pilot Study.

Journal of clinical medicine·2026
Same author

Splenic Abscess in Patients With Prior History of Enteric Fever: A Case Series.

Cureus·2026
Same author

Treatment Algorithm for Patients with Obesity in India: A Joint Consensus by Endocrine Society of India and Obesity Surgeons Society of India.

Obesity surgery·2026
Same author

Long-term nutritional outcomes after bariatric surgery: A multicentre study by the Obesity and Metabolic Surgery Society of India.

Journal of minimal access surgery·2026
Same author

Pet dogs supporting caregivers of children with special needs.

Bioinformation·2026
Same author

Anesthetic Approaches in Obese Patients: A Pilot Study Comparing the Impact of Desflurane versus Propofol on IL 6 Levels in Bariatric Surgery.

Journal of research in pharmacy practice·2026

Related Experiment Video

Updated: Jul 10, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.6K

Polypill and Combination Therapy: Blood Pressure and Cardiovascular Risk Reduction.

Jinwook Park1, Chien-Wen Yang2, Yonghong Huan3

  • 1Department of Medicine, University of Louisville School of Medicine, Louisville, KY, USA. Jinwook.park@louisville.edu.

Current Cardiology Reports
|November 22, 2023
PubMed
Summary

Fixed-dose combination pills, including those made with pharmaceutical 3D printing, improve blood pressure control and adherence. These combination therapies offer a reduced pill burden for cardiovascular disease prevention.

Keywords:
3D printingAdherenceFixed-dose combinationHypertensionPolypillPrimary prevention

More Related Videos

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K

Related Experiment Videos

Last Updated: Jul 10, 2025

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis
07:51

Hydra, a Computer-Based Platform for Aiding Clinicians in Cardiovascular Analysis and Diagnosis

Published on: September 26, 2018

7.6K
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.7K
Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia
11:06

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

2.0K

Area of Science:

  • Pharmaceutical Sciences
  • Cardiology
  • Medical Technology

Background:

  • Increasing polypharmacy, especially for cardioprotective medications, presents challenges in patient adherence and management.
  • Fixed-dose combination (FDC) medications offer a strategy to reduce pill burden.
  • Pharmaceutical 3D printing technology enables the creation of single tablets with multiple medications and varied release profiles.

Purpose of the Study:

  • To review the evidence supporting the use of combination pills for managing cardiovascular disease.
  • To explore the role of pharmaceutical 3D printing in developing advanced FDC therapies.
  • To assess the impact of FDC on blood pressure control and patient adherence.

Main Methods:

  • Review of recent randomized controlled trials and studies on FDC medications.
  • Examination of emerging pharmaceutical 3D printing technologies (e.g., powder-based, fused deposition modeling, semisolid extrusion).
  • Analysis of data on blood pressure control rates, adherence, and adverse events associated with FDC therapy.

Main Results:

  • Recent studies show higher blood pressure control rates with quadpill regimens versus monotherapy.
  • Low-dose triple FDC improved 6-month blood pressure control compared to usual care.
  • FDC therapy is supported for primary and secondary cardiovascular disease prevention with no significant increase in adverse events.
  • Pharmaceutical 3D printing offers flexibility, affordability, and feasibility for clinical FDC utilization.

Conclusions:

  • Fixed-dose combination therapy effectively reduces pill burden, potentially improving adherence and efficacy in cardiovascular disease management.
  • Pharmaceutical 3D printing is a promising technology for creating tailored FDC medications.
  • Multidisciplinary approaches and further research are needed to optimize FDC therapy and initial antihypertensive treatment strategies.